Fig. 5.
LY2109761 reduces liver metastasis and prolongs survival of Balb/c mice. A, 1×105 CT26-Luc cells were injected into spleens of Balb/c mice and mice assigned to the treatment group were given LY2109761 (50 mg/kg) orally twice daily. Bioluminescence images, taken after 23 days of splenic injection, are presented. B, Data represents average liver weight from control and LY2109761-treated mice (*P<0.01 compared to control, Student's t-test). C, To determine the survival of mice treated with LY2109761, mice were randomly divided into control group (n=7) and LY2109761-treated group (n=8). Mice were sacrificed when they were moribund and the day of sacrifice was considered the day of death for survival evaluation. Data represents the survival curve of control and LY2109761-treated mice (*P<0.001 compared to control, log-rank test). Each experiment was repeated three times with similar results.